InSite Vision Completes $9 Million Private Financing

InSite Vision -- an ophthalmic therapeutics, diagnostics and drug-delivery company -announced it has completed its previously announced $9 million private financing of common stock and warrants for common stock. New York-based Paramount BioCapital, Inc. served as the placement agent for this financing. "With this financing completed, we are now able to more fully concentrate on completing our Phase III pivotal trials with AzaSite, as well as our other programs," said S. Kumar Chandrasekaran, InSite Vision's president and chief executive officer.

()a href="http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20050526005779&ndmHsc=v2*A1116586800000*B1117227901000*DgroupByDate*J2*N1000122&newsLang=en&beanID=1229976837&viewID=news_view" target="_blank">BioSpace